Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casirivimab and Imdevimab vs Standard Antivirals in Hospitalized COVID-19
NCT05502081Phase 4Completed
- Sponsor
- Mansoura University Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, single-blind trial of casirivimab + imdevimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Mansoura University Hospital. Primary endpoints: 28-days Mortality Rate, Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit up to 60 days and 1 more. Started Sep 2022; status: completed.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05502081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502081.